$JSPR News

Jasper Therapeutics Received Notice Of Non-Compliance With Nasdaq Minimum Bid Requirements On June 3

Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

TD Cowen Downgrades Jasper Therapeutics to Hold

RBC Capital Maintains Sector Perform on Jasper Therapeutics, Lowers Price Target to $3

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7

Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $7

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics Q4 EPS $(0.32) Beats $(0.64) Estimate

Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria - Slideshow

Jasper Therapeutics reports updated data from briquilimab studies

Jasper Therapeutics shares are trading lower. The company reported updated clinical data from BEACON Phase 1b/2a study of subcutaneous briquilimab in chronic spontaneous urticaria.

Jasper Therapeutics shares are trading lower. The company reported updated clinical data from BEACON Phase 1b/2a study of subcutaneous briquilimab in chronic spontaneous urticaria.

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript

Jasper Therapeutics Reports Updated Clinical Data From BEACON Phase 1b/2a Study Of Subcutaneous Briquilimab In Adult Participants With CSU, As Well As From Open Label Extension Study In CSU And CIndU

Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth